{"trials":[{"id":5845,"nct_id":"NCT07610369","title":"The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease","sponsor":"Yale University","registry_url":"https://clinicaltrials.gov/study/NCT07610369","tracker_url":"publication.php?id=5845","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-28","start_date":"2026-07-10","primary_completion_date":"2030-07","completion_date":"2030-07","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":40,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Depression","Parkinson's Disease (PD)"],"interventions":[{"name":"Psilocybin (drug)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"ce511e3de8dae05034afdb25043c5e28d581eecc32497eda1b36dd3837c67ae4","facility":"Yale University","city":"New Haven","region":"Connecticut","country":"United States","lat":41.308149999999998,"lon":-72.928160000000005}],"countries":["United States"]},{"id":3604,"nct_id":"NCT04123314","title":"Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's Disease","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT04123314","tracker_url":"publication.php?id=3604","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-04","start_date":"2021-03-24","primary_completion_date":"2027-06-30","completion_date":"2027-09-30","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Depressive Symptoms","Depression","Alzheimer Disease","Mild Cognitive Impairment"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3590,"nct_id":"NCT06355414","title":"Psilocybin and Affective Function in Chronic Lower Back Pain Depression","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT06355414","tracker_url":"publication.php?id=3590","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-04","start_date":"2024-04-22","primary_completion_date":"2026-12-30","completion_date":"2026-12-30","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":40,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Chronic Low-back Pain","Depression"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Methylphenidate","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"b1b7385307b2710c76b5175c36619a7edcaff39e015a0a2e8cb2e1b125a2f6bb","facility":"Johns Hopkins University School of Medicine","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3687,"nct_id":"NCT04932434","title":"Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: a Pilot Study","sponsor":"Joshua Woolley, MD, PhD","registry_url":"https://clinicaltrials.gov/study/NCT04932434","tracker_url":"publication.php?id=3687","status":"COMPLETED","status_label":"Completed","status_verified_date":"2026-08","last_update_date":"2026-09-03","start_date":"2021-08-15","primary_completion_date":"2024-12-31","completion_date":"2024-12-31","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":12,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Parkinson Disease","Depression","Anxiety"],"interventions":[{"name":"Psilocybin therapy","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"7f09a842484186a75c6232177464293472d56c43d4d49f24f37efcb6c9cbbbb8","facility":"University of California, San Francisco","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942}],"countries":["United States"]},{"id":3562,"nct_id":"NCT06899165","title":"Processing Intergenerational Trauma With Psilocybin-Assisted Therapy","sponsor":"Rachel Yehuda","registry_url":"https://clinicaltrials.gov/study/NCT06899165","tracker_url":"publication.php?id=3562","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-08","last_update_date":"2026-08-13","start_date":"2026-08-28","primary_completion_date":"2029-05-31","completion_date":"2030-01-02","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":100,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Psychological Stress","Depression","Anxiety"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Integration sessions","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"41d7ef563025697eae67dcbab6ec20d0cf94934cb7a21f3999e9b581e150f205","facility":"The Parsons Research Center for Psychedelic Healing","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005}],"countries":["United States"]},{"id":3674,"nct_id":"NCT06801041","title":"TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors","sponsor":"M.D. Anderson Cancer Center","registry_url":"https://clinicaltrials.gov/study/NCT06801041","tracker_url":"publication.php?id=3674","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-08","last_update_date":"2026-08-12","start_date":"2025-05-23","primary_completion_date":"2027-03-31","completion_date":"2029-03-31","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"SUPPORTIVE_CARE","masking":"NONE"},"conditions":["Depression","Anxiety","Cancer"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"cc8da94c896719bab57ed8dd47266c0ce0664ad555799300d442f1fe89aa2942","facility":"The University of Texas M. D. Anderson Cancer Center","city":"Houston","region":"Texas","country":"United States","lat":29.763280000000002,"lon":-95.36327}],"countries":["United States"]},{"id":3642,"nct_id":"NCT06512194","title":"An Investigation of Strategies to Understand and Optimize the Antidepressant Effects of Psilocybin (The OPTIMIZE Study)","sponsor":"Charles Raison","registry_url":"https://clinicaltrials.gov/study/NCT06512194","tracker_url":"publication.php?id=3642","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-08","last_update_date":"2026-08-10","start_date":"2025-05-13","primary_completion_date":"2029-05","completion_date":"2029-05","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":141,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Depression"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)","type":"DEVICE"},{"name":"Sham taVNS","type":"DEVICE"}],"substances":["psilocybin"],"sites":[{"key":"e6baef990fbeb7d39fe3ae6170b4504d185d11acfac4b251c03198f2bd0ccd03","facility":"Vail Health Behavioral Health","city":"Edwards","region":"Colorado","country":"United States","lat":39.64499,"lon":-106.5942}],"countries":["United States"]},{"id":3561,"nct_id":"NCT06455293","title":"The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease","sponsor":"Joshua Woolley, MD, PhD","registry_url":"https://clinicaltrials.gov/study/NCT06455293","tracker_url":"publication.php?id=3561","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-05","last_update_date":"2026-08-07","start_date":"2024-08-19","primary_completion_date":"2027-06","completion_date":"2028-06","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":60,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Parkinson Disease","Depression"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Pimavanserin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"7f09a842484186a75c6232177464293472d56c43d4d49f24f37efcb6c9cbbbb8","facility":"University of California, San Francisco","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942}],"countries":["United States"]},{"id":3576,"nct_id":"NCT07336238","title":"A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and Depression","sponsor":"University of Washington","registry_url":"https://clinicaltrials.gov/study/NCT07336238","tracker_url":"publication.php?id=3576","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-31","start_date":"2026-05-19","primary_completion_date":"2026-12-01","completion_date":"2027-05-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":18,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Anxiety","Depression","Hematopoietic and Lymphatic System Neoplasm","Metastatic Malignant Solid Neoplasm"],"interventions":[{"name":"Psychotherapy","type":"BEHAVIORAL"},{"name":"Psilocybin","type":"DRUG"},{"name":"Survey Administration","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"27055592446b9d587e53a6321150bf4888fc2ba23be8770451328b59a69e7dd8","facility":"Fred Hutch/University of Washington Cancer Consortium","city":"Seattle","region":"Washington","country":"United States","lat":47.606209999999997,"lon":-122.33207}],"countries":["United States"]},{"id":3566,"nct_id":"NCT06820723","title":"A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe Anxiety","sponsor":"Ohio State University","registry_url":"https://clinicaltrials.gov/study/NCT06820723","tracker_url":"publication.php?id=3566","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-23","start_date":"2026-08-01","primary_completion_date":"2028-09","completion_date":"2028-11","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":40,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"OTHER","masking":"TRIPLE"},"conditions":["Depression","Anxiety","Major Depressive Disorder"],"interventions":[{"name":"CYB003","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin","psilocin"],"sites":[{"key":"53cdbf22033ee2308c3b87787fc126f7b960b463f408d5adce7f8bc3876c2e09","facility":"The Ohio State University Department of Psychiatry","city":"Columbus","region":"Ohio","country":"United States","lat":39.961179999999999,"lon":-82.99879}],"countries":["United States"]},{"id":3610,"nct_id":"NCT06341426","title":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2)","sponsor":"University Health Network, Toronto","registry_url":"https://clinicaltrials.gov/study/NCT06341426","tracker_url":"publication.php?id=3610","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-09","start_date":"2024-02-05","primary_completion_date":"2026-07-28","completion_date":"2026-12-28","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":92,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Major Depressive Disorder","Depression","Treatment-Resistant Depression","Mood Disorders"],"interventions":[{"name":"Single Psychedelic Dose Psilocybin","type":"DRUG"},{"name":"Two Psychedelic Doses Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"3590d22089fced0e188a9729567125a04d5a4db66af91f56a9d2d5c22d92597b","facility":"Toronto Western Hospital","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"2846642b890b09da9f32cb5c27a53f14767c23a4d2f66d979dc0e0c46d5d4cb3","facility":"Centre for Addiction and Mental Health (CAMH)","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864}],"countries":["Canada"]},{"id":3636,"nct_id":"NCT07582120","title":"A Pilot Mechanistic Study of Psilocybin-Assisted Therapy as a Treatment for Depression","sponsor":"Washington University School of Medicine","registry_url":"https://clinicaltrials.gov/study/NCT07582120","tracker_url":"publication.php?id=3636","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-05","last_update_date":"2026-05-20","start_date":"2026-06","primary_completion_date":"2031-06","completion_date":"2031-12","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":50,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"BASIC_SCIENCE","masking":"NONE"},"conditions":["Depression"],"interventions":[{"name":"Psilocybin (Usona Institute)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"c3de2ce8933f517f3be34bd70e3809569645c3f60c38d874765d86ee599b4223","facility":"Washington University School of Medicine","city":"St Louis","region":"Missouri","country":"United States","lat":38.627270000000003,"lon":-90.197890000000001}],"countries":["United States"]},{"id":3559,"nct_id":"NCT07565909","title":"A Phase 2 Sequential Dose-Finding Study of Preparation for Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of Depression","sponsor":"University of Washington","registry_url":"https://clinicaltrials.gov/study/NCT07565909","tracker_url":"publication.php?id=3559","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-04","last_update_date":"2026-05-04","start_date":"2026-06","primary_completion_date":"2027-12","completion_date":"2028-07","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":72,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SEQUENTIAL","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Depression","Anxiety"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[],"countries":[]},{"id":3509,"nct_id":"NCT05883540","title":"Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study)","sponsor":"University Hospital, Basel, Switzerland","registry_url":"https://clinicaltrials.gov/study/NCT05883540","tracker_url":"publication.php?id=3509","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-04","last_update_date":"2026-04-29","start_date":"2024-06-09","primary_completion_date":"2027-09","completion_date":"2028-05","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":60,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"SUPPORTIVE_CARE","masking":"QUADRUPLE"},"conditions":["Palliative Care","Pain","Anxiety","Depression","Demoralization","Psychological Distress","Quality of Life","Caregiver Burden","Fear of Death","Existential Distress"],"interventions":[{"name":"Lysergic Acid Diethylamide Tartrate","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"b28ad4c1ff8ff143bf7c2827ef2d114686d3c82f734dbd59191da6544cce398b","facility":"University Hospital Basel, Division of Clinical Pharmacology and Toxicology","city":"Basel","region":"","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999},{"key":"2609712e4f7c93509e6b3bbd8713f3242d8e8886b7480458304bd6280a3610bb","facility":"University Hospital Geneva, Palliative medicine department","city":"Collonge-Bellerive","region":"","country":"Switzerland","lat":46.250610000000002,"lon":6.20174},{"key":"f23fcd3a56bf1387f2f4eb3ab67dce163cae1cad5a551f60baa5d5c5a6da894b","facility":"Spital Uster AG, Division of Internal Medicine","city":"Uster","region":"","country":"Switzerland","lat":47.34713,"lon":8.7209099999999999},{"key":"90de5e97b9c55b0ae303eb535137dc52bdcbaab9be856fa3b3812a38fcbc8990","facility":"University Hospital Zurich, Clinic for Radio-Oncology, Competence Centre Palliative Care","city":"Zurich","region":"","country":"Switzerland","lat":47.366669999999999,"lon":8.5500000000000007}],"countries":["Switzerland"]},{"id":3681,"nct_id":"NCT06132178","title":"Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive Disorder","sponsor":"University of Texas at Austin","registry_url":"https://clinicaltrials.gov/study/NCT06132178","tracker_url":"publication.php?id=3681","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-11","last_update_date":"2025-11-26","start_date":"2025-01-10","primary_completion_date":"2029-12-31","completion_date":"2030-12-31","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":100,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"FACTORIAL","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Treatment Resistant Depression","MDD","Major Depressive Disorder","Recurrent Depression","Depression"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Accelerated intermittent theta burst (aiTBS) rTMS treatment","type":"DEVICE"},{"name":"Low-dose psilocybin","type":"DRUG"},{"name":"Sham Accelerated intermittent theta burst (aiTBS) rTMS treatment","type":"DEVICE"}],"substances":["psilocybin"],"sites":[{"key":"15784c018ae70fcfb16f6b7f984cc9132fb865e356d99c82ce788fa1bede4b39","facility":"Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600","city":"Austin","region":"Texas","country":"United States","lat":30.267150000000001,"lon":-97.74306}],"countries":["United States"]},{"id":3672,"nct_id":"NCT06372197","title":"Low-Income Group Psilocybin Assisted Therapy for Depression: A Feasibility Study","sponsor":"Matthew Hicks","registry_url":"https://clinicaltrials.gov/study/NCT06372197","tracker_url":"publication.php?id=3672","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-06","last_update_date":"2025-06-05","start_date":"2024-08-01","primary_completion_date":"2025-05-14","completion_date":"2025-05-14","study_type":"INTERVENTIONAL","phases":["NA"],"enrollment":{"count":20,"type":"ACTUAL"},"design":{"allocation":"NON_RANDOMIZED","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Depression"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"3f8d5218d2ffc6ea8473ce2d358bca1e459782dafccddcfd64ae7296c5336987","facility":"National University of Natural Medicine","city":"Portland","region":"Oregon","country":"United States","lat":45.523449999999997,"lon":-122.67621}],"countries":["United States"]},{"id":3530,"nct_id":"NCT05163496","title":"A Randomized, Placebo-controlled Trial of Psychedelic-assisted Psychotherapy With Single Dose Psilocybin for Frontline Clinicians Experiencing COVID-related Symptoms of Depression and Burnout","sponsor":"University of Washington","registry_url":"https://clinicaltrials.gov/study/NCT05163496","tracker_url":"publication.php?id=3530","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-03","last_update_date":"2025-03-18","start_date":"2022-03-03","primary_completion_date":"2023-12-30","completion_date":"2024-06-30","study_type":"INTERVENTIONAL","phases":["PHASE3"],"enrollment":{"count":30,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Burnout, Caregiver","Burnout, Professional","COVID-19","Depression","Post Traumatic Stress Disorder","Moral Injury"],"interventions":[{"name":"Psilocybin (Usona Institute)","type":"DRUG"},{"name":"Active placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"285f505708621e1f0fc9c6266c0110f7a1a84d0c2b08e83438836c81413008ad","facility":"University of Washington","city":"Seattle","region":"Washington","country":"United States","lat":47.606209999999997,"lon":-122.33207}],"countries":["United States"]},{"id":3430,"nct_id":"NCT05557643","title":"PAPR: Psilocybin-assisted Psychotherapy + Mindfulness-Based Stress Reduction (MBSR) for Front-line Healthcare Provider COVID-19 Related Burnout","sponsor":"University of Utah","registry_url":"https://clinicaltrials.gov/study/NCT05557643","tracker_url":"publication.php?id=3430","status":"COMPLETED","status_label":"Completed","status_verified_date":"2024-11","last_update_date":"2024-11-12","start_date":"2023-01-02","primary_completion_date":"2024-09-20","completion_date":"2024-09-20","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":24,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"SINGLE"},"conditions":["Depression","Burnout, Professional"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Mindfulness-Based Stress Reduction (MBSR)","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"0c0bb514818072629295ef417bfbdcf56e7ac0531b9beee0971543a5f874732e","facility":"Huntsman Mental Health Institute","city":"Salt Lake City","region":"Utah","country":"United States","lat":40.760779999999997,"lon":-111.89105000000001}],"countries":["United States"]},{"id":3445,"nct_id":"NCT06444243","title":"A Multi-centre, Double-blinded, Placebo-controlled, Randomised, Phase II Clinical Trial for Psilocybin-assisted Therapy for Alcohol Use Disorder","sponsor":"University of Sydney","registry_url":"https://clinicaltrials.gov/study/NCT06444243","tracker_url":"publication.php?id=3445","status":"UNKNOWN","status_label":"Unknown status","status_verified_date":"2024-06","last_update_date":"2024-06-10","start_date":"2024-09","primary_completion_date":"2025-07","completion_date":"2025-12","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":90,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"OTHER","masking":"DOUBLE"},"conditions":["Alcohol Use Disorder","Alcohol Dependence","Depression","Anxiety"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Niacin","type":"DRUG"}],"substances":["psilocybin"],"sites":[],"countries":[]},{"id":3434,"nct_id":"NCT04630964","title":"The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density - A Single Dose Randomized, Double Blind, Placebo- Controlled Phase 2 Positron Emission Tomography Study","sponsor":"Section for Affective Disorders; Northern Stockholm Psychiatry","registry_url":"https://clinicaltrials.gov/study/NCT04630964","tracker_url":"publication.php?id=3434","status":"COMPLETED","status_label":"Completed","status_verified_date":"2024-04","last_update_date":"2024-04-19","start_date":"2021-01-01","primary_completion_date":"2023-04-19","completion_date":"2024-04-18","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":35,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Major Depressive Disorder","Depression"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Niacin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"08ca08bcbae798f4e6b61831eefcfb8b407b6ae9119e1caf821ef346cd1389e6","facility":"Northern Stockholm Spychiatry Clinic","city":"Stockholm","region":"","country":"Sweden","lat":59.32938,"lon":18.068709999999999}],"countries":["Sweden"]},{"id":3629,"nct_id":"NCT06141876","title":"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-Assisted Psychotherapy in Treating Severe Depression Among Adults With Post-Traumatic Stress Disorder (PTSD).","sponsor":"Apex Labs Ltd.","registry_url":"https://clinicaltrials.gov/study/NCT06141876","tracker_url":"publication.php?id=3629","status":"UNKNOWN","status_label":"Unknown status","status_verified_date":"2023-11","last_update_date":"2023-11-29","start_date":"2023-12-15","primary_completion_date":"2025-06-15","completion_date":"2025-06-15","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":160,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Post-traumatic Stress Disorder","Depression"],"interventions":[{"name":"APEX-002-A02","type":"DRUG"},{"name":"Placebo","type":"OTHER"}],"substances":["psilocybin"],"sites":[],"countries":[]},{"id":3449,"nct_id":"NCT05594667","title":"Evaluating the Effect of Length of Time on Selective Serotonin Reuptake Inhibitors (SSRIs) on the Response to Psilocybin-assisted Therapy in Individuals With Mild-moderate Major Depressive Disorder (MDD)","sponsor":"Cybin Therapeutics Inc.","registry_url":"https://clinicaltrials.gov/study/NCT05594667","tracker_url":"publication.php?id=3449","status":"WITHDRAWN","status_label":"Withdrawn","status_verified_date":"2023-07","last_update_date":"2023-07-06","start_date":"2023-01-01","primary_completion_date":"2023-03-14","completion_date":"2023-03-14","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":0,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Depression","Major Depressive Disorder","Mild Depression","Moderate Depression","Depressive Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"a548c29a91f00e104ef28ac8ad761250fc7cefa257637d971bae85c1e19fc9fc","facility":"Centre for Neurology Studies x Upstream","city":"Abbotsford British Columbia","region":"British Columbia","country":"Canada","lat":49.057980000000001,"lon":-122.25257000000001}],"countries":["Canada"]},{"id":3556,"nct_id":"NCT02950467","title":"Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors","sponsor":"Joshua Woolley","registry_url":"https://clinicaltrials.gov/study/NCT02950467","tracker_url":"publication.php?id=3556","status":"COMPLETED","status_label":"Completed","status_verified_date":"2020-12","last_update_date":"2021-01-07","start_date":"2018-01-05","primary_completion_date":"2019-12-31","completion_date":"2019-12-31","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":30,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Distress","Depression","Grief"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Modified brief Supportive Expressive Group Therapy","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"7f09a842484186a75c6232177464293472d56c43d4d49f24f37efcb6c9cbbbb8","facility":"University of California, San Francisco","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942}],"countries":["United States"]}],"facets":{"countries":{"United States":182,"Canada":41,"Switzerland":21,"United Kingdom":18,"France":7,"Denmark":7,"Netherlands":6,"Czechia":5,"Ireland":5,"Sweden":4,"Israel":4,"Germany":3,"Australia":3,"Spain":2,"Brazil":2,"Pakistan":2,"Portugal":2,"Belgium":2,"Poland":1,"Austria":1,"New Zealand":1,"Finland":1,"Jordan":1,"Jamaica":1,"Argentina":1},"sponsors":{"Johns Hopkins University":31,"Yale University":16,"University Hospital, Basel, Switzerland":13,"COMPASS Pathways":9,"University of Wisconsin, Madison":9,"NYU Langone Health":9,"Centre for Addiction and Mental Health":8,"University Health Network, Toronto":5,"University of Calgary":5,"King's College London":5,"University of Washington":5,"Imperial College London":5,"University of Zurich":5,"MycoMedica Life Sciences PBC":4,"Joshua Woolley, MD, PhD":4,"University of New Mexico":4,"Usona Institute":4,"Centre Hospitalier Universitaire de Nīmes":4,"Washington University School of Medicine":4,"University of California, Los Angeles":4,"M.D. Anderson Cancer Center":3,"University of Colorado, Denver":3,"University of California, San Diego":3,"University of Alabama at Birmingham":3,"Sheppard Pratt Health System":3,"Unity Health Toronto":2,"University of British Columbia":2,"Emory University":2,"University of Minnesota":2,"Charles Raison":2,"Yvan Beaussant, MD, MSci":2,"Francisco A Moreno":2,"Ohio State University":2,"Khyber Medical University Peshawar":2,"University of California, Berkeley":2,"Sunstone Medical":2,"Robin Carhart-Harris, PhD, MA":2,"Section for Affective Disorders; Northern Stockholm Psychiatry":2,"Anders Fink-Jensen, MD, DMSci":2,"TRYP Therapeutics":2,"Beersheva Mental Health Center":2,"University of California, San Francisco":2,"Gitte Moos Knudsen":2,"University of Utah":2,"Brown University":1,"National Institute on Aging (NIA)":1,"Brigham and Women's Hospital":1,"Oregon Health and Science University":1,"Peter Hendricks":1,"Centre Hospitalier St Anne":1,"Lakshmi N Yatham":1,"Jennifer Mitchell":1,"McMaster University":1,"ARQ National Psychotrauma Centre":1,"University of Nebraska":1,"Region Skane":1,"VA Office of Research and Development":1,"Rachel Yehuda":1,"Sharmin Ghaznavi":1,"Nathan Brashares Sackett":1,"The University of Texas Health Science Center, Houston":1,"Roswell Park Cancer Institute":1,"Claudio N Soares":1,"Nicky Mehtani, MD, MPH":1,"James J. Peters Veterans Affairs Medical Center":1,"Trent Emerick":1,"University of Southern California":1,"Joshua Rosenblat":1,"Tel-Aviv Sourasky Medical Center":1,"Scottsdale Research Institute":1,"Pontifícia Universidade Católica do Rio de Janeiro":1,"Diamond Therapeutics Inc.":1,"Bruyère Health Research Institute.":1,"Ottawa Hospital Research Institute":1,"University of Pennsylvania":1,"Anthony P King":1,"University of Virginia":1,"Manoj Doss":1,"Alan Davis":1,"University Medical Center Groningen":1,"University of North Carolina, Chapel Hill":1,"Stanford University":1,"Portland VA Research Foundation, Inc":1,"Kyle Greenway":1,"Sunnybrook Health Sciences Centre":1,"Indiana University":1,"Federal University of Latin American Integration":1,"Medical University of Vienna":1,"Gustavo Vazquez":1,"Psyence Australia Pty Ltd":1,"Marissa Raymond-Flesch, MD, MPH":1,"Gabriella Gobbi":1,"Hadassah Medical Organization":1,"Nantes University Hospital":1,"Baylor College of Medicine":1,"Rotem Petranker":1,"University of Chicago":1,"University of Iowa":1,"University College, London":1,"University of Texas at Austin":1,"Charles S. Grob, M.D.":1,"Peggy C Nopoulos":1,"Anna Rose Childress, Ph.D.":1,"Kevin Murnane":1,"University Hospital, Geneva":1,"Healing Advocacy Fund":1,"Maastricht University":1,"Matthew Hicks":1,"National University of Natural Medicine":1,"Icahn School of Medicine at Mount Sinai":1,"Kevin Boehnke":1,"Felix Mueller":1,"University of Otago":1,"Insel Gruppe AG, University Hospital Bern":1,"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center":1,"Central Institute of Mental Health, Mannheim":1,"Filament Health Corp.":1,"Western University, Canada":1,"University Hospital, Ghent":1,"University of Arizona":1,"Clairvoyant Therapeutics":1,"Brugmann University Hospital":1,"Empower Research Inc":1,"University of Sydney":1,"Nova Mentis Life Science Corp":1,"Massachusetts General Hospital":1,"Multidisciplinary Association for Psychedelic Studies":1,"Apex Labs Ltd.":1,"Milan Scheidegger":1,"Lobe Sciences Ltd.":1,"Brain and Cognition Discovery Foundation":1,"The Roots to Thrive Society for Psychedelic Therapy":1,"Cybin Therapeutics Inc.":1,"Halucenex Life Sciences Inc.":1,"Combat Stress":1,"Optimi Health Corporation":1,"New York State Psychiatric Institute":1,"Keith Heinzerling":1,"NWTraumatherapies":1,"Beckley Psytech Limited":1,"Wake Network, Inc.":1,"National Institute of Mental Health, Czech Republic":1,"National Council of Scientific and Technical Research, Argentina":1,"Maryland Oncology Hematology, PA":1,"Joshua Woolley":1,"University of Helsinki":1},"phases":{"PHASE2":157,"PHASE1":112,"EARLY_PHASE1":24,"NA":16,"PHASE3":12},"conditions":{"Healthy":26,"Depression":23,"Major Depressive Disorder":23,"Treatment Resistant Depression":20,"PTSD":13,"Alcohol Use Disorder":13,"Anxiety":13,"Psilocybin":12,"Psychedelic Experiences":9,"Opioid Use Disorder":9,"Post Traumatic Stress Disorder":7,"Depression - Major Depressive Disorder":7,"Obsessive-Compulsive Disorder":6,"Advanced Cancer":6,"Demoralization":6,"Anorexia Nervosa":6,"Cancer":6,"Healthy Volunteers":5,"Depressive Disorder":5,"PTSD - Post Traumatic Stress Disorder":4,"Methamphetamine Use Disorder":4,"Anhedonia":4,"Psychological Distress":4,"Alcohol Use Disorder (AUD)":4,"Hematopoietic and Lymphatic System Neoplasm":4,"Depressive Disorder, Major":4,"Major Depressive Disorder (MDD)":4,"Alcohol Dependence":4,"Depressive Symptoms":3,"Suicidal Ideation":3,"Healthy Volunteer":3,"Stage IV Melanoma":3,"Major Depression":3,"Pain Management":3,"Metastatic Malignant Solid Neoplasm":3,"Chronic Pain":3,"Fibromyalgia":3,"PTSD Symptoms":2,"Nicotine Dependence":2,"Borderline Personality Disorder":2,"Treatment-resistant Depression (TRD)":2,"Stage IV Solid Tumor Cancer":2,"Stage IV Sarcoma of Bone":2,"Stage IV Lymphoma":2,"Endocrine Cancer":2,"Psychedelic Effects in Healthy Volunteers":2,"Depression, Anxiety":2,"Chronic Low-back Pain":2,"Parkinson Disease":2,"Existential Distress":2,"Treatment-Resistant Depression":2,"Aging":2,"Bipolar II Disorder":2,"Suicidality":2,"Malignant Solid Neoplasm":2,"Autism Spectrum Disorder":2,"Migraine":2,"Grief":2,"OCD":2,"Addiction":2,"Tobacco Use Disorder":2,"Substance Use Disorders":2,"Treatment-resistant Depression":2,"Treatment-Resistant Major Depressive Disorder":2,"MDD":2,"Substance Use Disorder (SUD)":2,"Healthy Participants":2,"Anxiety Disorders":2,"Depressive Disorder, Treatment-Resistant":2,"Hallucinogens":2,"Sleep":2,"Burnout, Professional":2,"Migraine Headache":2,"Cluster Headache":2,"Mood Change":2,"Phase I":1,"Alzheimer's Disease":1,"Chronic PTSD":1,"PTSD, Post Traumatic Stress Disorder":1,"Amnestic Mild Cognitive Impairment":1,"Neuropathy":1,"Mood (Psychological Function)":1,"Well Being":1,"Mood":1,"Well-Being, Psychological":1,"Parkinson's Disease (PD)":1,"Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI":1,"Chronic Pelvic Pain":1,"Borderline Personality Pathology":1,"Emotion Dysregulation":1,"Older Adults (65-85 Years)":1,"Music Intervention":1,"Emotional Blunting":1,"Bipolar II Depression":1,"Premenstrual Dysphoric Disorder ( PMDD)":1,"PMDD":1,"Psilocybin-Assisted Psychotherapy":1,"Persisting Symptoms After Concussion":1,"Anhedonia in Healthy Volunteers":1,"Older Adults (50-90 Years)":1,"Post Traumatic Stress Disorder PTSD":1,"Intimate Partner Violence (IPV)":1,"Alzheimer Disease":1,"Mild Cognitive Impairment":1,"Posttraumatic Stress Disorder":1,"Breast Cancer":1,"Ovarian Cancer":1,"Investigating the Importance of the Subjective Psychedelic Experience":1,"Burnout":1,"Burnout, Healthcare Workers":1,"Cannabis Use Disorder, Moderate":1,"Cannabis Use Disorder, Severe":1,"Posttraumatic Stress Disorder (PTSD)":1,"Chronic Low Back Pain (CLBP)":1,"Physical Therapy":1,"Pancreas Cancer":1,"Biliary Tract Cancer":1,"Gastrointestinal Cancer":1,"Longevity":1,"Biomarkers of Aging":1,"Psychological Stress":1,"Depression, Bipolar":1,"Generalized Anxiety Disorder (GAD)":1,"Human Immunodeficiency Virus (HIV)":1,"Amyotrophic Lateral Sclerosis":1,"Spinal Cord Injury":1,"Veteran":1,"Bipolar Depression":1,"Postoperative Pain":1,"Mental Health":1,"Opioid-Related Disorders":1,"Pain Management and Care":1,"Advanced Cancers":1,"Smokers With Chronic Pain":1,"Post-Traumatic Stress Disorder, PTSD":1,"Vagus Nerve Stimulation":1,"Healthy Adults":1,"Functional Neurological Disorder":1,"Healthy Controls":1,"Post-Traumatic Stress Disorder (PTSD)":1,"Distress, Emotional":1,"Perception Disorders":1,"Loneliness":1,"Mood Disorders":1,"Obsessive Compulsive Disorder (OCD)":1,"Depressive Sympotoms":1,"Caregiver Distress":1,"Prolonged Grief Disorder":1,"Neuroimaging":1,"Healthy Participants With Lower-than-average Mental Well-being":1,"Cocaine-Related Disorders":1,"Lung Non-Small Cell Carcinoma":1,"Unipolar Depression":1,"Obsessive - Compulsive Disorder":1,"Substance-Related Disorders":1,"Chemically-Induced Disorders":1,"Stimulant-Use Disorder":1,"COPD (Chronic Obstructive Pulmonary Disease)":1,"ALS (Amyotrophic Lateral Sclerosis)":1,"MS (Multiple Sclerosis)":1,"Atypical Parkinson Disease":1,"Refractory Depression":1,"Cognitive Behavioral Therapy":1,"Palliative Care":1,"Pain":1,"Quality of Life":1,"Caregiver Burden":1,"Fear of Death":1,"Amphetamine-Related Disorders":1,"Cocaine Use Disorder":1,"Cannabis Use Disorder":1,"Safety":1,"Fibromyalgia, Primary":1,"Transdiagnostic":1,"Substance Use":1,"IBS - Irritable Bowel Syndrome":1,"Stress Disorders, Traumatic":1,"Stress Disorders, Post-Traumatic":1,"Trauma and Stressor Related Disorders":1,"Mental Disorder":1,"Adjustment Disorder":1,"Adjustment Disorder With Anxious Mood":1,"Cancer Cachexia":1,"Cancer of Endometrium":1,"Cancer of Kidney":1,"Cancer of Prostate":1,"Cancer of the Breast":1,"Cancer of Stomach":1,"Cancer Melanoma Skin":1,"Cancer Pancreas":1,"Placebo - Control":1,"Hospice":1,"Terminal Illness":1,"Cancer-related Problem/Condition":1,"Psychotherapy":1,"Terminal Cancer":1,"Cancer Terminal":1,"Stroke":1,"Chronic Stroke":1,"Intracerebral Haemorrhage":1,"Intracerebral Haemorrhage (ICH)":1,"Intracerebral Hemorrhage Basal Ganglia":1,"Ischemic Stroke":1,"Ischemic Stroke and Hemorrhagic Stroke":1,"Hemiparesis After Stroke":1,"Hemiplegia Following Ischemic Stroke":1,"Hemiplegia and Hemiparesis":1,"Hemiplegia and/or Hemiparesis Following Stroke":1,"Middle Cerebral Artery Stroke":1,"Major Depressive Diorder":1,"Irritable Bowel Syndrome":1,"Gambling Disorder":1,"Phantom Limb Pain":1,"Stuttering":1,"Self Harm":1,"Opioid Dependence":1,"Alcohol Abuse":1,"Recurrent Depression":1,"Obsessive-compulsive Disorder":1,"Psychogenic Nonepileptic Seizures":1,"Reinforcement, Psychology":1,"Post-Treatment Lyme Disease":1,"Chronic Lyme Disease":1,"Lyme Disease, Chronic":1,"Hematopoietic and Lymphoid Cell Neoplasm":1,"Perception Disturbance":1,"Visual Suppression":1,"Meditation":1,"Microdosing":1,"Personal Experience of Substance-assisted Therapy Using Psilocybin, MDMA, and LSD":1,"Chronic Neuropathic Pain":1,"Neuropharmacological Investigation of Ayahuasca Constituents DMT and Harmine":1,"Alcohol-Related Disorders":1,"Burnout, Caregiver":1,"COVID-19":1,"Moral Injury":1,"Basic Science":1,"Binge Eating Disorder":1,"Stimulant Use Disorder":1,"Disorders of Consciousness":1,"Obsessive-compulsive Disorder (OCD)":1,"Severe Alcohol Use Disorder":1,"Psychotherapy, Group":1,"Fragile X Syndrome":1,"Behavior":1,"Cognitive Dysfunction":1,"Alcoholism":1,"Post-Traumatic Stress Disorder":1,"Post-traumatic Stress Disorder":1,"Post-Traumatic Headache":1,"Side Effect of Drug":1,"QTc Interval":1,"Pharmacokinetics":1,"End of Life":1,"Mild Depression":1,"Moderate Depression":1,"Treatment Resistant Disorders":1,"Amnesia":1,"Mood Disturbance":1,"Sleep Disturbance":1,"Drug Effect":1,"Health, Subjective":1,"Psilocin Toxicity":1,"Psilocybin Toxicity":1,"Psilocybin Causing Adverse Effects in Therapeutic Use":1,"Body Dysmorphic Disorders":1,"Trauma, Nervous System":1,"Short Lasting Unilateral Neuralgiform Headache Attacks":1,"Anxiety and Depression":1,"Religious or Spiritual Problem":1,"Patients":1,"Cognitive Change":1,"Creativity":1,"Altered Waking States of Consciousness in Healthy Humans":1,"Distress":1,"Parkinson Disease Psychosis":1,"Severe Depression":1,"Pharmacologic Actions":1,"Central Nervous System Agents":1,"Therapeutic Uses":1,"Psychotropic Drugs":1},"statuses":{"RECRUITING":103,"COMPLETED":97,"ACTIVE_NOT_RECRUITING":33,"NOT_YET_RECRUITING":33,"UNKNOWN":16,"WITHDRAWN":14,"TERMINATED":7,"ENROLLING_BY_INVITATION":3,"SUSPENDED":2}},"years":{"2018":1,"2021":3,"2022":1,"2023":3,"2024":6,"2025":3,"2026":6},"statuses":{"Recruiting":10,"Completed":6,"Active, not recruiting":2,"Not yet recruiting":2,"Unknown status":2,"Withdrawn":1},"conditions":{"Depression":23,"Anxiety":8,"Major Depressive Disorder":5,"Parkinson Disease":2,"Burnout, Professional":2,"Parkinson's Disease (PD)":1,"Depressive Symptoms":1,"Alzheimer Disease":1,"Mild Cognitive Impairment":1,"Chronic Low-back Pain":1,"Psychological Stress":1,"Cancer":1,"Hematopoietic and Lymphatic System Neoplasm":1,"Metastatic Malignant Solid Neoplasm":1,"Treatment-Resistant Depression":1,"Mood Disorders":1,"Palliative Care":1,"Pain":1,"Demoralization":1,"Psychological Distress":1,"Quality of Life":1,"Caregiver Burden":1,"Fear of Death":1,"Existential Distress":1,"Treatment Resistant Depression":1,"MDD":1,"Recurrent Depression":1,"Burnout, Caregiver":1,"COVID-19":1,"Post Traumatic Stress Disorder":1,"Moral Injury":1,"Alcohol Use Disorder":1,"Alcohol Dependence":1,"Post-traumatic Stress Disorder":1,"Mild Depression":1,"Moderate Depression":1,"Depressive Disorder":1,"Distress":1,"Grief":1},"sites":[{"key":"ce511e3de8dae05034afdb25043c5e28d581eecc32497eda1b36dd3837c67ae4","facility":"Yale University","city":"New Haven","region":"Connecticut","country":"United States","lat":41.308149999999998,"lon":-72.928160000000005},{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"b1b7385307b2710c76b5175c36619a7edcaff39e015a0a2e8cb2e1b125a2f6bb","facility":"Johns Hopkins University School of Medicine","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"7f09a842484186a75c6232177464293472d56c43d4d49f24f37efcb6c9cbbbb8","facility":"University of California, San Francisco","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942},{"key":"41d7ef563025697eae67dcbab6ec20d0cf94934cb7a21f3999e9b581e150f205","facility":"The Parsons Research Center for Psychedelic Healing","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"cc8da94c896719bab57ed8dd47266c0ce0664ad555799300d442f1fe89aa2942","facility":"The University of Texas M. D. Anderson Cancer Center","city":"Houston","region":"Texas","country":"United States","lat":29.763280000000002,"lon":-95.36327},{"key":"e6baef990fbeb7d39fe3ae6170b4504d185d11acfac4b251c03198f2bd0ccd03","facility":"Vail Health Behavioral Health","city":"Edwards","region":"Colorado","country":"United States","lat":39.64499,"lon":-106.5942},{"key":"27055592446b9d587e53a6321150bf4888fc2ba23be8770451328b59a69e7dd8","facility":"Fred Hutch/University of Washington Cancer Consortium","city":"Seattle","region":"Washington","country":"United States","lat":47.606209999999997,"lon":-122.33207},{"key":"53cdbf22033ee2308c3b87787fc126f7b960b463f408d5adce7f8bc3876c2e09","facility":"The Ohio State University Department of Psychiatry","city":"Columbus","region":"Ohio","country":"United States","lat":39.961179999999999,"lon":-82.99879},{"key":"3590d22089fced0e188a9729567125a04d5a4db66af91f56a9d2d5c22d92597b","facility":"Toronto Western Hospital","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"2846642b890b09da9f32cb5c27a53f14767c23a4d2f66d979dc0e0c46d5d4cb3","facility":"Centre for Addiction and Mental Health (CAMH)","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"c3de2ce8933f517f3be34bd70e3809569645c3f60c38d874765d86ee599b4223","facility":"Washington University School of Medicine","city":"St Louis","region":"Missouri","country":"United States","lat":38.627270000000003,"lon":-90.197890000000001},{"key":"b28ad4c1ff8ff143bf7c2827ef2d114686d3c82f734dbd59191da6544cce398b","facility":"University Hospital Basel, Division of Clinical Pharmacology and Toxicology","city":"Basel","region":"","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999},{"key":"2609712e4f7c93509e6b3bbd8713f3242d8e8886b7480458304bd6280a3610bb","facility":"University Hospital Geneva, Palliative medicine department","city":"Collonge-Bellerive","region":"","country":"Switzerland","lat":46.250610000000002,"lon":6.20174},{"key":"f23fcd3a56bf1387f2f4eb3ab67dce163cae1cad5a551f60baa5d5c5a6da894b","facility":"Spital Uster AG, Division of Internal Medicine","city":"Uster","region":"","country":"Switzerland","lat":47.34713,"lon":8.7209099999999999},{"key":"90de5e97b9c55b0ae303eb535137dc52bdcbaab9be856fa3b3812a38fcbc8990","facility":"University Hospital Zurich, Clinic for Radio-Oncology, Competence Centre Palliative Care","city":"Zurich","region":"","country":"Switzerland","lat":47.366669999999999,"lon":8.5500000000000007},{"key":"15784c018ae70fcfb16f6b7f984cc9132fb865e356d99c82ce788fa1bede4b39","facility":"Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600","city":"Austin","region":"Texas","country":"United States","lat":30.267150000000001,"lon":-97.74306},{"key":"3f8d5218d2ffc6ea8473ce2d358bca1e459782dafccddcfd64ae7296c5336987","facility":"National University of Natural Medicine","city":"Portland","region":"Oregon","country":"United States","lat":45.523449999999997,"lon":-122.67621},{"key":"285f505708621e1f0fc9c6266c0110f7a1a84d0c2b08e83438836c81413008ad","facility":"University of Washington","city":"Seattle","region":"Washington","country":"United States","lat":47.606209999999997,"lon":-122.33207},{"key":"0c0bb514818072629295ef417bfbdcf56e7ac0531b9beee0971543a5f874732e","facility":"Huntsman Mental Health Institute","city":"Salt Lake City","region":"Utah","country":"United States","lat":40.760779999999997,"lon":-111.89105000000001},{"key":"08ca08bcbae798f4e6b61831eefcfb8b407b6ae9119e1caf821ef346cd1389e6","facility":"Northern Stockholm Spychiatry Clinic","city":"Stockholm","region":"","country":"Sweden","lat":59.32938,"lon":18.068709999999999},{"key":"a548c29a91f00e104ef28ac8ad761250fc7cefa257637d971bae85c1e19fc9fc","facility":"Centre for Neurology Studies x Upstream","city":"Abbotsford British Columbia","region":"British Columbia","country":"Canada","lat":49.057980000000001,"lon":-122.25257000000001}],"enrollment":{"sum":1254,"known_trials":23},"registry_checked_at_utc":"2026-10-09 01:24:43"}